Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications

Toxins (Basel). 2019 Oct 13;11(10):597. doi: 10.3390/toxins11100597.

Abstract

Atrial fibrillation (AF) is the most prevalent arrhythmia in the general population. There is a close association between chronic kidney disease (CKD) and AF. In recent years, attention has been focused on the relationship between AF and uremic toxins, including indoxyl sulfate (IS). Several animal studies have shown that IS promotes the development and progression of AF. IS has been shown to cause fibrosis and inflammation in the myocardium and exacerbate AF by causing oxidative stress and reducing antioxidative defense. Administration of AST-120, an absorbent of uremic toxins, decreases uremic toxin-induced AF in rodents. We have recently reported that patients with a higher serum IS level exhibit a higher rate of AF recurrence after catheter ablation, with serum IS being a significant predictor of AF recurrence. In this review, we discuss the possible mechanisms behind the AF-promoting effects of uremic toxins and summarize the reported clinical studies of uremic toxin-induced AF.

Keywords: atrial fibrillation; chronic kidney disease; indoxyl sulfate; uremic toxin.

Publication types

  • Review

MeSH terms

  • Animals
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / epidemiology
  • Atrial Fibrillation* / etiology
  • Atrial Fibrillation* / physiopathology
  • Carbon / therapeutic use
  • Humans
  • Indican / therapeutic use
  • Oxides / therapeutic use
  • Renal Insufficiency, Chronic / complications
  • Toxins, Biological*
  • Uremia*

Substances

  • Oxides
  • Toxins, Biological
  • Carbon
  • AST 120
  • Indican